Finally, we intend to increase the practicality of our model by incorporating other resistance mechanisms commonly observed in treated EGFR-m NSCLC and feature other targeted therapies in combination with EGFR inhibitors. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.